Uniphore Appoints Ravi Mayuram as New Chief Technology Officer
14.8.2024 16:00:00 EEST | Business Wire | Press release
Uniphore, one of the world’s largest AI-native, enterprise-class companies, today announced the appointment of Ravi Mayuram as the company’s new Chief Technology Officer (CTO). Mayuram brings over 25 years of experience in engineering leadership and is poised to further Uniphore's leadership in Enterprise AI.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240814179209/en/
Ravi Mayuram, CTO of Uniphore. (Photo: Business Wire)
At Uniphore, Mayuram will lead the engineering team and take on the scaling up of Uniphore’s engineering platform, technology and AI groups, while ensuring the highest standards of security and performance.
Mayuram comes to Uniphore with a deep leadership background, having held several senior technical and management positions at leading software companies including Couchbase, BEA, HP, Informix, Oracle, and Siebel Systems. As an engineering leader, he has built teams from the ground up – in both established companies and startups – where he has been responsible for building systems, including operating systems, distributed databases, PaaS, SaaS as well as Edge and IoT systems.
Most recently, Mayuram was the Chief Development Officer at Luminary Cloud, where he led Products, Design and Engineering. Before that he was CTO of Couchbase, a leading cloud-native NoSQL database company, where he oversaw innovation, development and delivery of their popular database platform, and was instrumental in making them a successful public company. He has also led innovations in the areas of social graph, search and analytics at Oracle, and helped to initiate the company’s Cloud Collaboration Platform. His startup experience includes BroadBand Office (a Kleiner-Perkins venture), and Plumtree (acquired by BEA).
“It is with tremendous excitement that we welcome Ravi Mayuram to the Uniphore leadership team,” said Umesh Sachdev, CEO and co-founder of Uniphore. “As Uniphore becomes the preferred AI partner for the world’s largest enterprises, I am confident Ravi will help turbocharge our AI leadership and innovation into the future.”
Mayuram expressed enthusiasm about joining Uniphore, stating, “I am honored to join Uniphore at such a pivotal time in the company’s journey. Uniphore’s culture of AI innovation is unlike any other in the industry with technology that is tried, tested and trusted by the biggest companies. I am eager to work with this talented team of world-class engineers and leaders to further advance Uniphore’s technology and deliver even greater value to customers.”
For additional information on the U and Q product lines, please click here. To stay up to date with the latest commentary, follow Uniphore’s blog, or connect on LinkedIn, X, Facebook, or Instagram.
About Uniphore
Uniphore is one of the largest B2B AI-native companies – decades-proven, built-for-scale, and designed for the Enterprise. The company drives business outcomes, across multiple industry verticals, and the largest global deployments. Uniphore infuses AI into every part of the Enterprise that impacts the customer. We deliver the only multimodal AI architecture centered on customers that combines Generative AI, Knowledge AI and Emotion AI and Workflow Automation and a co-pilot to guide you. We understand better than anyone how to capture voice, video, text, and how to analyze all types of data. As AI becomes more powerful, every part of the Enterprise that impacts the customer will be disrupted. We believe the future will run on the connective tissue between people, machines and data: all in service of creating the most human processes and experiences for customers and employees.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240814179209/en/
Contacts
For more information about Uniphore, please contact: pr@uniphore.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobius Renewables Acquires Air Liquide’s Biogas Production Activities in the United States, France, Norway, and Sweden4.5.2026 09:45:00 EEST | Press release
Mobius Renewables today announced the closing of the acquisition of Air Liquide’s biogas production activities in the United States, France, Norway, and Sweden. The acquisition includes six operating landfill gas-to-RNG (Renewable Natural Gas) sites in the U.S., five operating farm waste sites in France, and a 51% interest in Redo Biosolutions with production and distribution assets across Norway and Sweden. The acquired portfolio will be a meaningful addition to Mobius Renewables (“the Company”), a global, vertically integrated low carbon fuels platform established in December 2025 by funds managed by IFM Investors to accelerate the development, production, distribution, and commercialization of RNG at scale across North America and Europe. The Company is headquartered in Houston, Texas with additional offices in the United States, France, Norway, and Sweden. With this transaction, the establishment of Mobius Renewables is complete, and GreenGasUSA and the acquired portfolio will oper
Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease2.5.2026 00:28:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-
Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 19:08:00 EEST | Press release
A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom